CorMedix Announces FDA Priority Review for REZZAYO S-NDA
The FDA accepted the supplemental NDA with a target action date of Q1 2027, supported by the ReSPECT Phase III trial. This milestone marks a significant regulatory step toward addressing the high mortality rates associated with invasive fungal diseases.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed